ABIVAX Société Anonyme (NASDAQ:ABVX) is Great Point Partners LLC’s 3rd Largest Position

Great Point Partners LLC trimmed its stake in ABIVAX Société Anonyme (NASDAQ:ABVX) by 0.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,472,188 shares of the company’s stock after selling 16,295 shares during the period. ABIVAX Société Anonyme makes up approximately 6.3% of Great Point Partners LLC’s portfolio, making the stock its 3rd biggest holding. Great Point Partners LLC owned approximately 3.93% of ABIVAX Société Anonyme worth $32,682,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ABVX. Janus Henderson Group PLC increased its stake in ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares during the last quarter. Kennedy Capital Management LLC increased its position in shares of ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares during the last quarter. Capstone Investment Advisors LLC raised its holdings in shares of ABIVAX Société Anonyme by 9.0% during the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after buying an additional 5,199 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of ABIVAX Société Anonyme during the 1st quarter valued at about $81,000. Finally, Rosalind Advisors Inc. bought a new stake in ABIVAX Société Anonyme in the 1st quarter worth approximately $5,411,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Laidlaw started coverage on shares of ABIVAX Société Anonyme in a research report on Monday, July 29th. They set a “buy” rating and a $48.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, ABIVAX Société Anonyme presently has an average rating of “Moderate Buy” and a consensus target price of $36.50.

ABIVAX Société Anonyme Stock Down 3.9 %

Shares of ABVX stock opened at $10.86 on Tuesday. The business has a 50-day moving average of $11.78 and a 200 day moving average of $13.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.08 and a current ratio of 3.04. ABIVAX Société Anonyme has a 1-year low of $7.99 and a 1-year high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.